Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,362 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06443307Recruiting
Study of Liposomal Irinotecan in Advanced Colorectal Cancer
This study tests a new form of chemotherapy called liposomal irinotecan (Nal-IRI) for people with advanced colorectal cancer or other solid tumors. The goal is to see how well it works and how safe it is in real-world settings.
Beijing, Beijing MunicipalityAges Any age - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06468696Recruiting
Scarless thyroid surgery study
This trial is testing a specific type of scarless thyroid surgery (through the chest) and seeing how well it works for people with thyroid tumors that haven't spread. It might be a good fit if you want to avoid a neck scar.
Xi'an, ShaanxiAges 18–75 - NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30 - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06536257Recruiting
Personalized immunotherapy prediction for melanoma and other cancers
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Sydney, New South WalesAges 18 years+ - NCT06549946RecruitingPhase 1/Phase 2
Ixovex-1 injection alone or with another drug for advanced solid tumors
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
LondonAges 18 years+ - NCT06551142RecruitingPhase 1
Study of GSK5764227 for advanced solid tumors
This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.
Stanford, CaliforniaAges 18 years+ - NCT06551909Recruiting
Radiation plus immunotherapy for glioblastoma patients
This trial tests a combination of radiation and immunotherapy for people with glioblastoma. The goal is to see if adding immunotherapy to standard radiation can improve outcomes.
Milan, MIAges 18–80 - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06561178Recruiting
Blood Test to Monitor Esophageal Cancer After Surgery
This trial looks at whether a personalized blood test can detect cancer returning after surgery for esophageal cancer. It tests people who had chemoradiotherapy before surgery and still had some cancer remaining in the removed tissue. The goal is to use the blood test to catch any remaining or returning cancer early.
Guangzhou, GuangdongAges Any age - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+ - NCT06614647Recruiting
Digital follow-up for colorectal cancer survivors
This trial tests a smartphone-based follow-up program for people who have been treated for early-stage colorectal cancer. The goal is to see if a digital, need-based care guide can replace standard follow-up visits.
Herning, Central JutlandAges 18 years+ - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,362 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.